TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34304234

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen 30 mg/kg with IV placebo
Number of subjects: 66

Group type: COMPARATOR
Intervention: IV acetaminophen 15 mg/kg with oral placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen
Number of subjects: 66

Group type: COMPARATOR
Intervention: IV acetaminophen
Number of subjects: 66
Study: 35613801

Group type: EXPERIMENTAL
Intervention: Endovenous microwave ablation (EMA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 180
Study: 33475414

Group type: EXPERIMENTAL
Intervention: Sepsis leaflet
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Traditional vaccination leaflet
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control leaflet
Number of subjects: 585
Study: 32197291

Group type: EXPERIMENTAL
Intervention: Atopic disease (asthma)
Number of subjects: 1468033

Group type: EXPERIMENTAL
Intervention: Atopic disease (atopic dermatitis)
Number of subjects: 1468033

Group type: EXPERIMENTAL
Intervention: Atopic disease (allergic rhinitis)
Number of subjects: 1468033
Study: 34654038

Group type: EXPERIMENTAL
Intervention: Desk + Program
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Desk Only
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Program Only
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control
Number of subjects: 95
Study: 34008756

Group type: EXPERIMENTAL
Intervention: Eight-gene signature (CBX7, JADE2, IGF2BP3, OR2W6P, PRAME, TICRR, KIF4A, and PIMREG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eight-gene signature
Number of subjects: 0
Study: 32690730

Group type: EXPERIMENTAL
Intervention: Not using drugs
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Lower psychological distress
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Good mental health scores
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Better physical health
Number of subjects: 425
Study: 34438327

Group type: EXPERIMENTAL
Intervention: Riboflavin deficiency diet (1.48 mg riboflavin/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control diet (16.48 mg riboflavin/kg)
Number of subjects: 40
Study: 32958820

Group type: EXPERIMENTAL
Intervention: Elective nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin) plus erlotinib
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Elective nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin) plus erlotinib
Number of subjects: 352

Group type: COMPARATOR
Intervention: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin)
Number of subjects: 352
Study: 35236727

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Usual care wait list control
Number of subjects: 281
Study: 33338463

Group type: EXPERIMENTAL
Intervention: Standard ultrasound-guided subacromial injections (40 mg triamcinolone acetonide)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dual-target injections (20 mg triamcinolone acetonide for LHBT and supraspinatus tendons)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 60
Study: 35179585

Group type: EXPERIMENTAL
Intervention: Poor prognostic understanding regarding life expectancy estimates
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Discordance regarding life expectancy estimates
Number of subjects: 541
Study: 33476068

Group type: EXPERIMENTAL
Intervention: SHAPE-NVL
Number of subjects: 88

Group type: COMPARATOR
Intervention: VYC-20L
Number of subjects: 88
Study: 35697559

Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 240
Study: 33589279

Group type: EXPERIMENTAL
Intervention: Extended oral antibiotic prophylaxis for 7 days after discharge
Number of subjects: 3855

Group type: COMPARATOR
Intervention: No extended oral antibiotic prophylaxis
Number of subjects: 3855
Study: 32909059

Group type: COMPARATOR
Intervention: Resistance exercise (RES)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Combined exercise (COMB: RES + AER)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aerobic exercise (AER)
Number of subjects: 12

Group type: COMPARATOR
Intervention: All exercise sessions (AER, RES, COMB)
Number of subjects: 12
Study: 35529777

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Combined Training (COMB)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 109
Study: 34244787

Group type: EXPERIMENTAL
Intervention: Integrated Coaching for Mood and Weight (I‐CARE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 34275872

Group type: EXPERIMENTAL
Intervention: Community-led HIVST
Number of subjects: 11150

Group type: COMPARATOR
Intervention: Paid distribution (PD)
Number of subjects: 11150
Study: 35334389

Group type: EXPERIMENTAL
Intervention: Active transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 35011059

Group type: EXPERIMENTAL
Intervention: 6 g fish oil daily for 6 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: 6 g soybean oil daily for 6 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: 3 g of each (fish oil and soybean oil) daily for 6 weeks
Number of subjects: 85
Study: 34187817

Group type: EXPERIMENTAL
Intervention: Preoperative imaging with magnetic resonance cholangiopancreatography (MRCP)
Number of subjects: 13680

Group type: COMPARATOR
Intervention: Expectant management (no preoperative imaging)
Number of subjects: 13680

Group type: EXPERIMENTAL
Intervention: Preoperative imaging with MRCP
Number of subjects: 13680
Study: 32024400

Group type: EXPERIMENTAL
Intervention: Cemented DM cup fixation (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cementless DM cup fixation (n = 30)
Number of subjects: 60
Study: 36113023

Group type: EXPERIMENTAL
Intervention: High-fiber, high-fruit and vegetable, low-fat dietary intervention
Number of subjects: 368

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Pre-trial dietary fiber intake
Number of subjects: 368
Study: 34530738

Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure management (< 120/80 mmHg)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Standard blood pressure management (< 140/90 mmHg)
Number of subjects: 173
Study: 34825264

Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium lactis Probio-M8 (2 × 10^10 log CFU/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium lactis Probio-M8
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 35593522

Group type: EXPERIMENTAL
Intervention: Injectable platelet-rich fibrin (PRF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 12
Study: 33720388

Group type: EXPERIMENTAL
Intervention: 1 mg/kg sugammadex
Number of subjects: 102

Group type: COMPARATOR
Intervention: 2 mg/kg sugammadex
Number of subjects: 102
Study: 32108888

Group type: EXPERIMENTAL
Intervention: 8-week home-based exercise program plus nurse consultations
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (brief nurse consultation)
Number of subjects: 140
Study: 35723242

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo intranasal spray
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo control protocol
Number of subjects: 112
Study: 33260523

Group type: EXPERIMENTAL
Intervention: Active cooking intervention (hands-on lesson)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Demonstration cooking intervention (observing a chef)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both conditions (active and demonstration)
Number of subjects: 0
Study: 32941962

Group type: EXPERIMENTAL
Intervention: Hyperopia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myopia
Number of subjects: 0
Study: 33257487

Group type: EXPERIMENTAL
Intervention: Champion support in implementation of the Back Skills Training (BeST) programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard training for physiotherapists without champion support
Number of subjects: 0
Study: 36413792

Group type: EXPERIMENTAL
Intervention: Low-dose Ara-C plus pegylated recombinant arginase BCT-100
Number of subjects: 83

Group type: COMPARATOR
Intervention: Low-dose Ara-C (LDAC)
Number of subjects: 83
Study: 33582621

Group type: EXPERIMENTAL
Intervention: Action observation therapy in addition to exercise (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Exercise alone (Control group, n = 18)
Number of subjects: 36
Study: 32398113

Group type: EXPERIMENTAL
Intervention: Propranolol (40-80 mg twice daily) in addition to standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone (i.e. anti-epileptic drugs or headache treatments)
Number of subjects: 0
Study: 36075235

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered after childbirth
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo administered after childbirth
Number of subjects: 33
Study: 33648495

Group type: EXPERIMENTAL
Intervention: Delay in seeking treatment for pelvic organ prolapse
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Factors associated with delay in treatment
Number of subjects: 123
Study: 32811613

Group type: EXPERIMENTAL
Intervention: Transcranial pulsed ultrasound combined with alteplase intravenous thrombolysis
Number of subjects: 82

Group type: COMPARATOR
Intervention: Alteplase intravenous thrombolytic treatment
Number of subjects: 82
Study: 34855212

Group type: EXPERIMENTAL
Intervention: StressProffen intervention (n = 84)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual-care control group (n = 88)
Number of subjects: 172
Study: 34101691

Group type: EXPERIMENTAL
Intervention: 1-week immobilization
Number of subjects: 111

Group type: COMPARATOR
Intervention: 3-week immobilization
Number of subjects: 111
Study: 33032585

Group type: EXPERIMENTAL
Intervention: Curcumin 5% ointment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vaseline ointment (placebo)
Number of subjects: 72
Study: 35096422

Group type: EXPERIMENTAL
Intervention: Suprachoroidal triamcinolone acetonide injection 4 mg/0.1 ml (SCTA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intravitreal triamcinolone acetonide 4 mg/0.1 ml (IVTA)
Number of subjects: 23
Study: 32247219

Group type: COMPARATOR
Intervention: Cole formula
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Duracher formula
Number of subjects: 135

Group type: COMPARATOR
Intervention: Khine formula
Number of subjects: 135
Study: 34438110

Group type: EXPERIMENTAL
Intervention: Lidocaine + Dexamethasone (3 cc 2% lidocaine + 1 cc dexamethasone, 4 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine alone (3 cc 2% lidocaine + 1 cc normal saline)
Number of subjects: 60
Study: 32500131

Group type: EXPERIMENTAL
Intervention: Oral caffeine (5 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 32009778

Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination (FDC) of gemigliptin (50 mg) and rosuvastatin (20 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Loose combination of gemigliptin (50 mg) and rosuvastatin (20 mg)
Number of subjects: 37
Study: 35658048

Group type: EXPERIMENTAL
Intervention: Conventional and speckle-tracking echocardiography
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Validation sample from the Copenhagen City Heart Study
Number of subjects: 1441
Study: 34948486

Group type: EXPERIMENTAL
Intervention: Early occupational therapy intervention program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 60
Study: 33791888

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 42
Study: 33498049

Group type: EXPERIMENTAL
Intervention: Vitamin D (150,000 IU daily for 3 days before surgery)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 32498098

Group type: EXPERIMENTAL
Intervention: MOSE technique
Number of subjects: 244

Group type: COMPARATOR
Intervention: Conventional technique without ROSE
Number of subjects: 244
Study: 35550031

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interscalene brachial plexus block (ISB)
Number of subjects: 60
Study: 33167040

Group type: EXPERIMENTAL
Intervention: Birth tourism (BT) infants
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Non-BT control infants
Number of subjects: 1755
Study: 32800386

Group type: EXPERIMENTAL
Intervention: Folic acid (400 μg) and vitamin-B12 (500 μg) supplementation
Number of subjects: 2919

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2919
Study: 35331681

Group type: EXPERIMENTAL
Intervention: Telestration group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional teaching group
Number of subjects: 20
Study: 33252627

Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36121303

Group type: EXPERIMENTAL
Intervention: PIEB interval of 35 minutes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PIEB interval of 40 minutes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PIEB interval of 45 minutes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PIEB interval of 50 minutes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PIEB interval of 55 minutes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DPE technique with ropivacaine 0.1% and sufentanil 0.5 μg/mL
Number of subjects: 100
Study: 33440301

Group type: EXPERIMENTAL
Intervention: Strategic Memory and Reasoning Training (SMART) (n = 38)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Brain Health Workshop (control) (n = 43)
Number of subjects: 81
Study: 34184930

Group type: EXPERIMENTAL
Intervention: Expanded quantitative urine culture (EQUC)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Standard urine culture (SUC)
Number of subjects: 225
Study: 32546834

Group type: EXPERIMENTAL
Intervention: Dynamic decision aid (DA)
Number of subjects: 2119

Group type: COMPARATOR
Intervention: Standard brochure (SB)
Number of subjects: 2119
Study: 34459055

Group type: EXPERIMENTAL
Intervention: AccuVein arm
Number of subjects: 304

Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 304
Study: 33990239

Group type: EXPERIMENTAL
Intervention: DBT PE completers
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: DBT PE initiators
Number of subjects: 35

Group type: COMPARATOR
Intervention: DBT only
Number of subjects: 35
Study: 35159318

Group type: EXPERIMENTAL
Intervention: Selenium yeast (200 µg/day) and coenzyme Q10 (200 mg/day), n = 118
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo, n = 101
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10 supplementation
Number of subjects: 219
Study: 33745082

Group type: EXPERIMENTAL
Intervention: Utilization of infertility services
Number of subjects: 12456

Group type: COMPARATOR
Intervention: Not accessing infertility services
Number of subjects: 12456

Group type: EXPERIMENTAL
Intervention: Healthcare utilization trends
Number of subjects: 12456

Group type: EXPERIMENTAL
Intervention: Insurance status
Number of subjects: 12456

Group type: EXPERIMENTAL
Intervention: Insurance status and utilization of infertility care
Number of subjects: 12456
Study: 32917271

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35081595

Group type: EXPERIMENTAL
Intervention: Prehospital low titer group O whole blood (LTOWB)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard prehospital air medical care (including red cell transfusion and crystalloids)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Prehospital low titer group O whole blood (LTOWB) and Standard care
Number of subjects: 86
Study: 34145880

Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg twice a day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 32570237

Group type: EXPERIMENTAL
Intervention: Low-dose OIT (20 mL; n = 19)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-dose OIT (100 mL; n = 14)
Number of subjects: 33
Study: 33103925

Group type: EXPERIMENTAL
Intervention: 20-session schema group therapy plus treatment as usual (TAU) (n = 28)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone (n = 14)
Number of subjects: 42
Study: 33704925

Group type: COMPARATOR
Intervention: Single-ascending-dose oral edaravone (30 to 300 mg)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Multiple-dose edaravone (120 mg/day for 5 or 8 days)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 100 mg oral edaravone
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Oral edaravone formulations
Number of subjects: 140
Study: 33267545

Group type: COMPARATOR
Intervention: Ca(OH)2 apexification (group 1, n=6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedure (REP) (group 2, n=6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both groups (Ca(OH)2 apexification and REP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ca(OH)2 apexification
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedure (REP)
Number of subjects: 12
Study: 36046952

Group type: EXPERIMENTAL
Intervention: 20 mg oral melatonin liquid
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 50 mg oral melatonin liquid
Number of subjects: 2
Study: 33657114

Group type: EXPERIMENTAL
Intervention: Early convalescent plasma (CP) therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Deferred convalescent plasma (CP) therapy
Number of subjects: 58
Study: 32087837

Group type: EXPERIMENTAL
Intervention: web‐based relapse prevention program (e‐SMARPP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: web‐based self‐monitoring (control group)
Number of subjects: 48
Study: 34907443

Group type: EXPERIMENTAL
Intervention: Vibrating alarm watch
Number of subjects: 243

Group type: COMPARATOR
Intervention: Non-alarming watch (Control)
Number of subjects: 243
Study: 33811684

Group type: EXPERIMENTAL
Intervention: Music Video (MV) therapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study: 35253117

Group type: COMPARATOR
Intervention: Magnesium sulfate (placebo-controlled trial)
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Final prediction model including IVH, PVL, gestational age, and gender
Number of subjects: 1889
Study: 33200221

Group type: EXPERIMENTAL
Intervention: hsa_circRNA_100876 inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: differentially expressed circRNAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hsa_circRNA_100876
Number of subjects: 0
Study: 33345938

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Induction of labor and expectant management
Number of subjects: 1116
Study: 35690008

Group type: EXPERIMENTAL
Intervention: Children and adolescents with SM
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group without SM
Number of subjects: 28
Study: 34526088

Group type: EXPERIMENTAL
Intervention: Feedback and facilitated meetings
Number of subjects: 1900000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1900000
Study: 32568327

Group type: EXPERIMENTAL
Intervention: HCD diet containing 0.2% UA (UAL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HCD diet containing 0.4% UA (UAH)
Number of subjects: 32

Group type: COMPARATOR
Intervention: HCD diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: NCD
Number of subjects: 32
Study: 34951444

Group type: EXPERIMENTAL
Intervention: CHD-PAL intervention (eight 30-min videoconferencing sessions over 20 weeks with an interventionist + Fitbit + exercise prescription)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparator (Fitbit + exercise prescription)
Number of subjects: 60
Study: 35351445

Group type: EXPERIMENTAL
Intervention: Norgestrel 0.075 mg progestogen-only pill
Number of subjects: 52
Study: 33758132

Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL nalbuphine with 10 mL 0.1% ropivacaine
Number of subjects: 180

Group type: COMPARATOR
Intervention: 0.3 μg/mL sufentanil with 10 mL 0.1% ropivacaine
Number of subjects: 180
Study: 32552387

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/tablet) + anti-TB therapy
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo + anti-TB therapy
Number of subjects: 348
Study: 35358648

Group type: EXPERIMENTAL
Intervention: Community-based, patient-centered rehabilitation program
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Trial within cohort (TWIC) design
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: TWIC design
Number of subjects: 74
Study: 33621479

Group type: EXPERIMENTAL
Intervention: Dermabond tissue adhesive
Number of subjects: 38

Group type: COMPARATOR
Intervention: 5/0 Prolene sutures
Number of subjects: 38
Study: 35988120

Group type: EXPERIMENTAL
Intervention: +EFT
Number of subjects: 104

Group type: COMPARATOR
Intervention: +SR
Number of subjects: 104
Study: 32940699

Group type: EXPERIMENTAL
Intervention: COBRA-light treatment arm
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: COBRA treatment arm
Number of subjects: 36
Study: 32974656

Group type: EXPERIMENTAL
Intervention: Internet-delivered Acceptance and Commitment Therapy (ACT) for adolescents
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Internet-delivered Acceptance and Commitment Therapy (ACT) for parents
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Internet-delivered ACT for adolescents
Number of subjects: 28
Study: 35063241

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet with gluten (5 gr/day of gluten powder)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (5 gr of rice flour) with low FODMAP diet
Number of subjects: 49